Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Revenue of Trevi Therapeutics, Inc. (TRVI)
Revenue in 2023 (TTM): $
According to Trevi Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Trevi Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-123,000 | $-33,800,000 | $-29,097,000 | $-29,065,000 |
| 2022 | $ | $-43,000 | $-29,864,000 | $-29,188,000 | $-29,152,000 |
| 2021 | $ | $-50,000 | $-32,426,000 | $-33,961,000 | $-33,940,000 |
| 2020 | $ | $-47,000 | $-32,442,000 | $-32,776,000 | $-32,758,000 |
| 2019 | $ | $-39,000 | $-26,606,000 | $-26,068,000 | $-26,050,000 |
| 2018 | $ | $-23,000 | $-18,385,000 | $-20,669,000 | $-20,545,000 |
| 2017 | $ | $ | $-8,188,000 | $-12,886,000 | $-12,860,000 |
| 2016 | $ | $-4,000 | $-8,621,000 | $-11,095,000 | $-11,087,000 |